No difference between Macugen and triamcinolone

Article

A study, which was halted before the completion of enrolment, failed to demonstrate any difference in the visual outcomes or safety concerns in patients with neovascularization secondary to age-related macular degeneration (AMD) who were treated with photodynamic therapy (PDT) in combination with either intravitreal injections of Macugen (pegaptanib sodium) or triamcinolone

A study, which was halted before the completion of enrolment, failed to demonstrate any difference in the visual outcomes or safety concerns in patients with neovascularization secondary to age-related macular degeneration (AMD) who were treated with photodynamic therapy (PDT) in combination with either intravitreal injections of Macugen (pegaptanib sodium) or triamcinolone, according to a presentation at this year's meeting of the Association for Research in Vision and Ophthalmology (ARVO).

Peter Kaiser from the Cole Eye Institute, Ohio, USA presented the findings of the study in which patients were randomized to receive either PDT plus pegaptanib sodium 0.3 mg (n=38), PDT plus triamcinolone 1 mg (n=32) or triamcinolone 4 mg (n=41). The study was halted early, with only 111 patients of the intended 339 taking part.

After six-months follow-up there were no significant differences between groups in terms of the primary endpoint - a loss of 15 letters on the visual acuity test. All percentages were much lower than had been expected (PDT plus pegaptanib sodium 73.7%; PDT plus triamcinolone 81.3%; triamcinolone 73.2%). There was also no significant difference in the area of neovascularization between the two steroid groups and the pegaptanib sodium group. All groups demonstrated a significant reduction in central retinal thickness.

In terms of safety, 14% of patients receiving triamcinolone had significant spikes in their intraocular pressure, although it did not result in any acute losses in visual acuity. Overall the safety was considered to be reasonably good in each group.

Despite the early termination of enrolment, patients will continue treatment until the 12-month endpoint.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jay Chhablani, MD, shares late-breaking data from the ArMaDa trial, investigating gene therapy for Geographic Atrophy and dry age-related macular degeneration, at EURETINA
Editorial advisory board member Alexandra Miere, MD, PhD, speaks about the ACTOR and HERMES studies at the 2025 European Society of Retina Specialists (EURETINA) Congress
María Berrocal, MD, speaks about the Vit-Buckle Society symposium hosted at the 2025 European Society of Retina Specialists (EURETINA) annual meeting
© 2025 MJH Life Sciences

All rights reserved.